Key result
THAQ acetylation improves anticancer activity against T cells via increased DNA binding and superoxide formation.
Why the study?
Hydroxy-9,10-anthraquinones have weaker biophysical interactions with DNA than anthracyclines due to formation of anionic species, limiting their anticancer potential.
Acetylation of THAQ improves its DNA binding and superoxide formation, leading to enhanced cytotoxicity against Jurkat T lymphocyte cells, suggesting potential as an alternative to anthracyclines.
Acetylation may enhance THAQ potency in vitro; leaves open translation to in vivo or clinical oncology.
Background: Hydroxy-9,10-anthraquinones form the core unit of anthracycline anticancer drugs and are close structural analogues to these drugs. Although they show close resemblance to anthracyclines in physicochemical characteristics and electrochemical behavior their biophysical interactions are somewhat weaker than anthracyclines which is a disadvantage. One reason is the formation of anionic species by hydroxy-9,10-anthraquinones. Hence if formation of anionic species is prevented there could be a possibility hydroxy-9,10-anthraquinones would bind DNA better. Procedure: For this 1, 2, 5, 8-tetrahydroxy-9,10-anthraquinone (THAQ) was acetylated to obtain a tetra-acetylated derivative (THAQ-ace) whose interaction with calf thymus DNA was studied using UV-Vis spectroscopy at different pH. Results: Binding constant values for THAQ-ace (~105) were higher than THAQ at different pH. Increase in binding constant was attributed to anionic species not formed for THAQ-ace at physiological pH. Hence, unlike THAQ, binding constant values for THAQ-ace interacting with calf thymus DNA did not show variation with pH. In fact, it remained more or less constant. Increase in size of the acetylated form (THAQ-ace) compared to THAQ had a negative influence on binding. THAQ-ace showed enhanced superoxide formation. Both DNA binding and superoxide formation were responsible for a significant improvement in anticancer activity for THAQ-ace compared to THAQ on Jurkat T lymphocyte cells. Conclusion: Binding constant values for THAQ-ace binding to DNA were close to that reported for some standard anthracyclines. Hence, suitable modification of the less costly hydroxy-9,10-anthraquinones could provide alternatives to anthracyclines in cancer chemotherapy.
No takes yet. Share an insight, caveat, or question.
Mukherjee et al. (2014) studied Cancer (Jurkat T lymphocyte cells). Tetra-acetylated derivative of 1,2,5,8-tetrahydroxy-9,10-anthraquinone (THAQ-ace) vs. 1,2,5,8-tetrahydroxy-9,10-anthraquinone (THAQ) was evaluated on DNA binding constant and cytotoxicity. Acetylation of THAQ to THAQ-ace increased its DNA binding constant and enhanced superoxide formation, leading to significant improvement in anticancer activity on Jurkat T lymphocyte cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: